GlassScriptPhysician profile
Scott C Poulton
NPI 1386655686
$6,640.44
in general payments reported to CMS, 2019-2025
26 companies · $476 in 2025
The $476 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $518 · 2020: $711 · 2021: $1,823 · 2022: $1,538 · 2023: $1,094 · 2024: $480 · 2025: $476.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,033 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $17.14.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,032.77 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $17.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $1,387.76 | 2019-2023 | Livalo, Seglentis |
| Glaxosmithkline, LLC. | $725.13 | 2020-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $548.51 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Takeda Pharmaceuticals U.S.A., INC. | $420.85 | 2019-2025 | Trintellix |
| Pfizer INC. | $415.53 | 2019-2025 | |
| Medicure Pharma INC. | $389.56 | 2021-2024 | Zypitamag |
| E.R. Squibb & Sons, L.L.C. | $383.31 | 2019-2025 | Eliquis, Camzyos |
| Astrazeneca Pharmaceuticals LP | $374.43 | 2021-2025 | Breztri, Farxiga |
| Novo Nordisk INC | $349.68 | 2020-2022 | |
| Amgen INC. | $320.78 | 2019-2025 | Repatha, Otezla, Repatha |
| Janssen Pharmaceuticals, INC | $239.50 | 2021-2023 | Xarelto |
| Amarin Pharma, INC. | $224.24 | 2020-2021 | |
| Biohaven Pharmaceuticals, INC. | $206.89 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $190.35 | 2021-2025 | Gardasil 9, Capvaxive, Vaxneuvance |
| Abbvie INC. | $173.26 | 2021-2024 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $46.29 | 2022 | |
| Exact Sciences Corporation | $37.61 | 2025 | Cologuard Collection Kit |
| Astellas Pharma US INC | $37.15 | 2020-2021 | |
| Eisai INC. | $33.05 | 2021 | |
| Sumitomo Pharma America, INC. | $29.12 | 2023 | Gemtesa |
| Almatica Pharma LLC | $24.50 | 2021 | |
| Sunovion Pharmaceuticals INC. | $21.50 | 2022 | |
| Lumenis, INC | $16.92 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $16.44 | 2019 | |
| Preventice Services, LLC | $15.44 | 2019 | |
| Allergan, INC. | $12.64 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Poulton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.